With 0.14 million shares changed hands, the volume of the stock remained heavier than its average volume of 40870.0 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $17.2513 whereas the lowest price it dropped to was $16.0. The 52-week range on PTN shows that it touched its highest point at $72.50 and its lowest point at $1.75 during that stretch. It currently has a 1-year price target of $54.33. Beta for the stock currently stands at 0.38.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PTN was down-trending over the past week, with a drop of -24.24%, but this was down by -20.00% over a month. Three-month performance surged to 56.13% while six-month performance rose 106.45%. The stock lost -71.17% in the past year, while it has lost -66.94% so far this year. A look at the trailing 12-month EPS for PTN yields -13.19 with Next year EPS estimates of -1.87. For the next quarter, that number is -2.35. This implies an EPS growth rate of 86.17% for this year and 57.95% for next year. EPS is expected to grow by 55.89% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 23.09%.
Float and Shares Shorts:
At present, 1.70 million PTN shares are outstanding with a float of 1.54 million shares on hand for trading. On 2025-11-28, short shares totaled 0.17 million, which was 1011.9999999999999 higher than short shares on 1745971200. In addition to Dr. Carl Spana Ph.D. as the firm’s Co-Founder, President, CEO & Director, Mr. Stephen T. Wills CPA, MST serves as its CFO, COO, Executive VP, Treasurer & Secretary.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-09-30, PTN reported revenue of $8847550.0 and operating income of $4661053.0. The EBITDA in the recently reported quarter was $4675440.0 and diluted EPS was $4.26.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PTN since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With PTN analysts setting a high price target of 60.0 and a low target of 50.0, the average target price over the next 12 months is 54.33333. Based on these targets, PTN could surge 275.0% to reach the target high and rise by 212.5% to reach the target low. Reaching the average price target will result in a growth of 239.58% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$2.51205 being high and -$2.51205 being low. For PTN, this leads to a yearly average estimate of -$2.51205.
